SABS
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing multi-specific human immunoglobulin G antibodies to treat autoimmune and immune disorders, with a proprietary platform using transchromosomic cattle to produce polyclonal antibodies without human plasma donors. The company's lead program, SAB-142, is a human anti-thymocyte globulin in Phase 2b development for type 1 diabetes, designed to preserve insulin-producing beta cells by modulating autoreactive T-lymphocytes. SAB-142 has demonstrated a clinically validated mechanism of action with no reported serum sickness or neutralizing anti-drug antibodies across approximately 800 human subjects, and the company initiated its registrational SAFEGUARD study in the third quarter of 2025.